Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: July 7, 2026
Event Date: July 7, 2026 (Pricing); July 9, 2026 (Closing)
Business Context: The Company, a Delaware corporation, priced a private offering of pre-funded warrants and accompanying warrants to an investor to raise capital for clinical trials, patent portfolio maintenance, and working capital.
Key Financial Metrics
- Net Proceeds: Approximately $2.7 million (after deducting placement agent fees and estimated offering expenses).
- Potential Additional Proceeds: Approximately $6 million if all warrants are fully exercised on a cash basis.
- Securities Issued:
- 2,112,677 Pre-Funded Warrants (exercise price $0.001).
- 2,112,677 Series F Warrants (exercise price $1.42; 5-year term).
- 2,112,677 Series G Warrants (exercise price $1.42; 18-month term).
- Combined Purchase Price: $1.419 per Pre-Funded Warrant and accompanying Warrants.
- Placement Agent Fees: 7.0% cash fee, 1.0% management fee, plus reimbursement of expenses up to $85,000 and issuance of 126,761 Placement Agent Warrants (exercise price $1.775).
Material Changes
This filing represents a material definitive agreement and unregistered sale of equity securities. The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement. The Company is obligated to seek shareholder approval for the issuance of the Warrants and underlying shares at its next annual meeting or a special meeting within 90 days of the closing date. The filing does not provide comparative financial data (revenue, profit, cash flow) as it is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
- Use of Proceeds: Funding clinical trials, maintaining/extending patent portfolio, and general corporate purposes.
- Registration Rights: The Company must file a resale registration statement within 15 calendar days and use commercially reasonable efforts to have it declared effective within 45 calendar days (or 75 days if under full review).
- Covenants: The Purchase Agreement prohibits the issuance of Common Stock or convertible securities for 60 days after the Effective Date and prohibits variable rate transactions for one year after the Effective Date.
- Ownership Limitations: Holders cannot exercise warrants if they would beneficially own more than 4.99% (or 9.99% at election) of outstanding shares post-exercise.
- Forward-Looking Statements: The filing includes standard disclaimers regarding future performance, clinical timelines, and regulatory approvals, noting that actual results may differ materially.
Investor Verification Checklist
- Verify the effectiveness of the Resale Registration Statement (Form S-3 or S-1) within the required 45-75 day window.
- Confirm the date and outcome of the shareholder vote required to approve the issuance of the Warrants and underlying shares.
- Monitor the Company's cash burn rate relative to the $2.7 million net proceeds to assess runway for clinical trials.
- Review the specific terms of the Placement Agent Warrants and their potential dilutive impact compared to the investor warrants.
- Check for any subsequent filings regarding the 60-day lock-up period on new equity issuances.